Healthcare Sales & Marketing Network News: Bone Pain

Searching News Database: Bone Pain

HSMN NewsFeed - 28 Jan 2022
Blueprint Medicines' AYVAKYT(R) (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Aug 2018
Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Jun 2018
Partner Therapeutics (PTx) Announces US FDA Approval of Leukine(R) (sargramostim) for the Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Mar 2018
Q Biomed Inc. Announces FDA Filing for Approval of a New Manufacturing Facility for Non-Opioid Strontium Chloride SR89 Injection USP for Relief of Cancer Bone Pain
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Feb 2018
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta(R) (pegfilgrastim)
Biopharmaceuticals Drug Delivery Regulatory

HSMN NewsFeed - 1 Feb 2018
Partner Therapeutics (PTx) Acquires Leukine(R) from Sanofi
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Aug 2016
Takeda Receives Marketing Authorization in Canada for NINLARO(TM) (ixazomib) in Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 27 Jul 2016
Coverage of INSIGHTEC's Exablate for Pain Palliation of Bone Metastases Expands to 99.8 Million Members in the US
Devices Oncology Reimbursement

HSMN NewsFeed - 7 Mar 2014
Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Biopharmaceuticals

HSMN NewsFeed - 22 Oct 2013
Amgen Acquires Filgrastim Franchise Rights From Roche In 100 Markets
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 13 Jun 2013
FDA Approves Amgen's XGEVA(R) (denosumab) For The Treatment Of Giant Cell Tumor Of Bone
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 26 Nov 2012
GE Healthcare Redefines Comfort, Confidence and Connectivity in Radiology at RSNA Conference
Devices Radiology

HSMN NewsFeed - 22 Oct 2012
FDA Approves New Non-Invasive, Non-Ionizing Radiation Therapy to Treat Pain from Bone Metastases
Devices Oncology FDA

HSMN NewsFeed - 30 Aug 2012
Teva Announces FDA Grants Approval for Tbo-filgrastim for the Treatment of Chemotherapy-Induced Neutropenia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 24 Jul 2012
Debiopharm Group(TM) - First Patient Treated in Phase III Study With Subcutaneous Administration of Debio 8206 for Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 1 Feb 2012
FDA approves Novartis drug Gleevec(R) label recommending extending treatment to three years for certain GIST patients after surgery
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 1 Nov 2011
FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE(R) in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 15 Sep 2011
KAI Pharmaceuticals Signs Agreement for Development and Commercialization of KAI-4169 in Japan with Ono Pharmaceutical
Biopharmaceuticals

HSMN NewsFeed - 23 Aug 2011
FDA Grants Fast Track Designation to Bayer's Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Aug 2011
New NCCN Patient Guidelines Help Patients Navigate the Maze of Breast Cancer Treatment Options
Oncology

HSMN NewsFeed - 15 Jul 2011
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 28 Jun 2011
Alternative Pain Therapy for Breast, Prostate and Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Jun 2011
Abbott Receives FDA Approval for a New Six-Month Formulation of Lupron Depot(R) (leuprolide acetate for depot suspension) for the Palliative Treatment of Advanced Prostate Cancer
Biopharmaceuticals Drug Delivery Oncology FDA

HSMN NewsFeed - 6 Jun 2011
Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 May 2011
Amgen Receives CHMP Positive Opinion for XGEVA (Denosumab) in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 24 Feb 2011
FDA Grants Genentech a Hearing on Avastin’s Use for Metastatic Breast Cancer in the United States
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Dec 2010
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Sep 2010
FDA Approves New Dosing for FASLODEX(R) (fulvestrant) Injection in Treatment of Metastatic Breast Cancer in HR+ Postmenopausal Women
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 4 Jun 2010
Bayer Presents Clinical Data on Alpharadin in Metastatic Castration-Resistant Prostate Cancer (CRPC)
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 May 2010
Takeda to Co-Promote VELCADE(R) (bortezomib) for Injection in Japan
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Jan 2010
FDA Approves Addition of Sustained Overall Survival Benefit to Label for VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Dec 2009
Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals

HSMN NewsFeed - 7 Dec 2009
VELCADE(R) (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up to 88 Percent in Patients with Previously Untreated Multiple Myeloma
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Nov 2009
Genentech Submits Supplemental Applications to FDA for Avastin Combined with Commonly Used Chemotherapies for Women with Advanced Breast Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 22 Sep 2009
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 Sep 2009
FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for VELCADE(R) (bortezomib) for Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Sep 2009
FDA to Review Supplement Containing Long-Term Survival Data For VELCADE(R) (bortezomib) For Injection
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Aug 2009
Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
Biopharmaceuticals Onology

HSMN NewsFeed - 22 Sep 2008
Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Aug 2008
New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Jun 2008
Odanacatib, an Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 May 2008
Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Mar 2008
Samaritan Pharmaceuticals Acquires Commercialization Rights to Market and Distribute Abiogen's Cancer Drug Abioklad in Greece, Cyprus and Turkey
Biopharmaceuticals Distribution

HSMN NewsFeed - 10 Mar 2008
Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Feb 2008
FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11
Biopharmaceuticals FDA

HSMN NewsFeed - 20 Dec 2007
Marketing of Viadur(R) (leuprolide acetate implant) to Phase Out by April 2008
Biopharmaceuticals

HSMN NewsFeed - 18 Dec 2007
Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Oct 2007
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Biopharmaceuticals Oncology

HSMN NewsFeed - 16 Oct 2007
FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia
Biopharmaceuticals

HSMN NewsFeed - 26 Sep 2007
New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Sep 2007
CyberKnife(R) System Shows Momentum as Treatment Option for Prostate Cancer
Devices Oncology

HSMN NewsFeed - 20 Sep 2007
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 17 Apr 2007
Reclast(R) Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Jan 2007
European Association of Nuclear Medicine Journal Article Reports New Data Regarding Administration of QUADRAMET(R) with Chemotherapy in Hormone Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jan 2007
Anthera Receives IND Approval from FDA to Begin Phase 2 'IMPACTS' Trial With A-001 for Prevention of Acute Chest Syndrome in Patients with Sickle Cell Disease
Biopharmaceuticals

HSMN NewsFeed - 18 Dec 2006
American Cancer Society Journal Article Reports New Data Regarding Repeated Administration of QUADRAMET(R)
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2006
Data Presented Today Show ARIMIDEX(R) Combined With Herceptin(R) Extended Progression-Free Survival in Patients With Advanced HER-2-Positive and Hormone Receptor-Positive Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Nov 2006
New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R) Treatment Compared With Standard Therapy
Biopharmaceuticals

HSMN NewsFeed - 17 Nov 2006
FOSRENOL(R) Data Show Evidence of Trends Towards Improved Bone Formation in CKD Stage 5 Patients, New Data Presented at ASN Meeting
Biopharmaceuticals

HSMN NewsFeed - 18 Oct 2006
Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Sep 2006
Cancer Patients Show Reduced Pain and Lower Analgesic Consumption Following Treatment with QUADRAMET(R)
Biopharmaceuticals Onoclogy

HSMN NewsFeed - 16 Sep 2006
Once-Yearly Reclast(R)* Demonstrates Highly Significant Fracture Risk Reductions in the Treatment of Postmenopausal Osteoporosis, New Study Shows
Biopharmaceuticals

HSMN NewsFeed - 12 Sep 2006
Endocare Receives FDA 510K Clearance to Market New Nitrogen-Based Cryoablation System for Destroying Tissue and Cancerous Tumors
Devices FDA

HSMN NewsFeed - 16 Jul 2006
Amgen Announces EVOLVE Trial(TM) To Investigate Impact of Sensipar(R)/Mimpara(R) (cinacalcet HCl) on Mortality and Cardiovascular Morbidity in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease Receiving Dialysis
Biopharmaceuticals

Return to NewsFeed

Additional items found! 119

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 119 additional stories matching:
Bone Pain
(Password required)

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!